Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Finding Key Collaborators in the Data
Posted on August 23rd, 2017 by Christine de Vries - Scheidegger in Pharma R&D
R&D is no longer a solely in-house process where Big Pharma researchers work diligently in secret to come up with the next blockbuster drug. Rising costs, patient needs, global trends, healthcare reform, changes in clinical development models and many other factors have altered the R&D landscape. In today’s environment, pharmaceutical firms must reach outward in order to innovate.To drive successful drug discovery and development, pharma companies have become increasingly reliant on fruitful collaborations with a variety of partners, including innovative biotech companies, contract research organizations (CROs), academic institutions and individual experts as well. Working with these outside partners supercharges internal R&D and creates shared risks and rewards among collaborators.
But the question then becomes: how do pharma companies find the right partners? The new white paper “Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships” suggests that the typical methods of networking, whether it’s exchanging business cards at conferences or calling up the author of a journal article you recently read, are not good enough anymore.
To locate the collaborators who will best suit their needs, companies must look into the data. Just as pharmaceutical R&D relies on big data for understanding diseases and developing drugs, now they must turn to sophisticated data analysis to help identify and qualify potential partners.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Christine de Vries - Scheidegger
Head of Market Development, Corporate R&D at Elsevier
- Chemists Concerned About How Their Field is Viewed
- As The Hive Evolves, More Companies Prepare to Join the Program
- As Drug Development Costs Skyrocket, AI Offers Some Hope
- Myelo Therapeutics Takes on Unmet Needs in Cancer
- Disrupting innovation: From geography, penguins and ocean currents to diagnosing disease by its smell